Sarwa Darwish Murad

Sarwa Darwish Murad

Auto-generated profile, based on publicly available information

Sarwa Darwish Murad

Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, ERN RARE-LIVER Affiliated Center for Rare Vascular Disorders, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
SMSarwa Darwish Murad
Sarwa Darwish Murad
WKW. Ray Kim
W. Ray Kim
DHDenise M. Harnois
Denise M. Harnois
DDDavid D. Douglas
David D. Douglas
JBJames Burton
James Burton
JHJulie K. Heimbach
Julie K. Heimbach

1 January 2010 in Hepatology
Verified
Journal Article
Closed access
PDF file
APAurelie Plessier
Aurelie Plessier
SDSarwa Darwish-Murad
Sarwa Darwish-Murad
MHManuel Hernández-Guerra
Manuel Hernández-Guerra
YCYann Consigny
Yann Consigny
FFFederica Fabris
Federica Fabris
DVDominique Valla
Dominique Valla

4 August 2009 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
SMSarwa Darwish Murad
Sarwa Darwish Murad
APAurelie Plessier
Aurelie Plessier
MHManuel Hernández-Guerra
Manuel Hernández-Guerra
FFFederica Fabris
Federica Fabris
CEChundamannil E. Eapen
Chundamannil E. Eapen
FLFor En-Vie (European Network For Vascular Disorders Of The Liver)
For En-Vie (European Network For Vascular Disorders Of The Liver)
The Budd–Chiari syndrome (BCS) is hepatic venous outflow obstruction. What is known about the syndrome is based on small studies of prevalent cases. To characterize the causes and treatment of incident BCS. Consecutive case series of patients with incident BCS, enrolled from October 2003 to October 2005 and followed until May 2006. Academic and nonacademic hospitals in France, Spain, Italy, Great Britain, Germany, Belgium, the Netherlands, Portugal, and Switzerland. Persons older than 16 years with definite hepatic outflow obstruction diagnosed by imaging. Persons with hepatic outflow obstruction due to heart failure, sinusoidal obstruction syndrome, cancer, or liver transplantation were excluded. Signs and symptoms; laboratory and imaging findings; diagnosis; treatment; and overall, transplantation-free, and intervention-free survival. 163 incident cases of BCS were identified. Median follow-up was 17 months (range, 0.1 to 31 months). Most patients (84%) had at least 1 thrombotic risk factor, and many (46%) had more than 1; the most common was myeloproliferative disorders (49% of 103 tested patients). Patients were mainly treated with anticoagulation (140 patients [86%]), transjugular intrahepatic portosystemic shunting (56 patients [34%]), or liver transplantation (20 patients [12%]), and 80 patients (49%) were managed noninvasively. Only 3 patients underwent surgical shunting. The survival rate was 87% (95% CI, 82% to 93%) at 1 year and 82% (CI, 75% to 88%) at 2 years. Treatment was not standardized across all centers, and data on important clinical variables were missing for some patients. Most patients with BCS have at least 1 thrombotic risk factor, and many have more than 1; myeloproliferative disorders are most common. One- and 2-year survival rates are good with contemporary management, which includes noninvasive therapies (anticoagulation and diuretics) and invasive techniques. Transjugular intrahepatic portosystemic shunting seems to have replaced surgical shunting as the most common invasive therapeutic procedure. Fifth Framework Programme of the European Commission.

1 September 2017 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
MIM. Arfan Ikram
M. Arfan Ikram
GBGuy G. O. Brusselle
Guy G. O. Brusselle
SMSarwa Darwish Murad
Sarwa Darwish Murad
CDCornelia M. van Duijn
Cornelia M. van Duijn
OFOscar H. Franco
Oscar H. Franco
AHAlbert Hofman
Albert Hofman
The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, otolaryngological, locomotor, and respiratory diseases. As of 2008, 14,926 subjects aged 45 years or over comprise the Rotterdam Study cohort. Since 2016, the cohort is being expanded by persons aged 40 years and over. The findings of the Rotterdam Study have been presented in over 1500 research articles and reports (see www.erasmus-epidemiology.nl/rotterdamstudy). This article gives the rationale of the study and its design. It also presents a summary of the major findings and an update of the objectives and methods.

1 August 2015 in European Journal of Epidemiology
Verified
Journal Article
Open access
PDF file
AHAlbert Hofman
Albert Hofman
GBGuy G. O. Brusselle
Guy G. O. Brusselle
SMSarwa Darwish Murad
Sarwa Darwish Murad
CDCornelia M. van Duijn
Cornelia M. van Duijn
OFOscar H. Franco
Oscar H. Franco
MVMeike W. Vernooij
Meike W. Vernooij
The Rotterdam Study is a prospective cohort study ongoing since 1990 in the city of Rotterdam in The Netherlands. The study targets cardiovascular, endocrine, hepatic, neurological, ophthalmic, psychiatric, dermatological, otolaryngological, locomotor, and respiratory diseases. As of 2008, 14,926 subjects aged 45 years or over comprise the Rotterdam Study cohort. The findings of the Rotterdam Study have been presented in over 1200 research articles and reports (see www.erasmus-epidemiology.nl/rotterdamstudy). This article gives the rationale of the study and its design. It also presents a summary of the major findings and an update of the objectives and methods.

1 September 2008 in Gastroenterology
Verified
Journal Article
Closed access
JGJuan Carlos García-Pagán
Juan Carlos García-Pagán
MHMathis Heydtmann
Mathis Heydtmann
SRSebastian Raffa
Sebastian Raffa
APAurélie Plessier
Aurélie Plessier
SMSarwa Murad
Sarwa Murad
JBJaume Bosch
Jaume Bosch